<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115697</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-HE-01</org_study_id>
    <nct_id>NCT03115697</nct_id>
  </id_info>
  <brief_title>High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.</brief_title>
  <official_title>High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit-A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design- Randomized Controlled trial Duration of enrolment-Feb-2016 to December 2017
      Sample size-120 patients Methodology We will include consecutive with advanced hepatic
      encephalopathy not responding to treatment of precipitants and on treatment with Lactulose
      and Rifaximin for 48 hours .

      Two groups will be divided. One arm -Lactulose and Rifaximin will be continued Second Arm -
      Plasmapheresis will be added to the standard medical care therapy.(Maximum of 3 sessions once
      in 24 hours/or alternate days with an follow up for 5 days)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2018</start_date>
  <completion_date type="Anticipated">April 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution in Hepatic Encephalopathy by 2 grades in both groups</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Hepatic Encephalopathy in both groups</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of mechanical ventilation in both groups</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival in both groups</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Systemic inflammatory response syndrome (SIRS) or sepsis as precipitants of Hepatic encephalopathy in both groups.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with failure of standard medical therapy in both groups.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Refractory Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Lactulose with Rifaximin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmapheresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmapheresis will be added to the standard medical care therapy.(Maximum of 3 sessions once in 24 hours/or alternate days with an follow up for 5 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>Lactulose 20 mL</description>
    <arm_group_label>Lactulose with Rifaximin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Rifaximin 550 BD</description>
    <arm_group_label>Lactulose with Rifaximin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmapheresis</intervention_name>
    <description>Plasmapheresis 8 hrly duration</description>
    <arm_group_label>Plasmapheresis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhotics

          -  Age between 18-70 years

          -  Hepatic encephalopathy -Grade 3-4

          -  Patients receiving Lactulose/Rifaximin for 48 hours and not showing improvement in
             Hepatic encephalopathy(Persistent Grade 3/4)

        Exclusion Criteria:

          -  Concomitant participation in an other clinical trial

          -  Patient receiving sedatives(propofol,etc) 24 hours prior.

          -  Patients with severe cardiopulmonary disease

          -  Pregnancy

          -  Human Immunodeficiency Virus

          -  Hepatocellular Carcinoma or extrahepatic malignancy

          -  Active uncontrolled sepsis with hemodynamic instability

          -  Chronic renal insufficiency on treatment with haemodialysis

          -  Uncontrolled bleed or patients in DIC

          -  Extremely moribund patients with expected survival of less than 48 hours on high
             vasopressor support

          -  Patients with moderate-severe Acute Respiratory Distress Syndrome (ARDS).

          -  Patients with Non Hepatic Coma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Harsh Vardhan Tevethia, MD</last_name>
    <phone>01146300000</phone>
    <email>hershey4686@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

